180 Life Sciences Année d'introduction en bourse
Quel est le Année d'introduction en bourse de 180 Life Sciences?
Le Année d'introduction en bourse de 180 Life Sciences Corp. est 2020
Quelle est la définition de Année d'introduction en bourse?
Le premier appel public à l'épargne est un type d'offre publique dans lequel les actions d'une entreprise sont généralement vendues à des investisseurs institutionnels qui, pour leur part, vendent au grand public, pour la première fois, sur une bourse de valeurs.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Année d'introduction en bourse des entreprises dans Health Care secteur sur NASDAQ par rapport à 180 Life Sciences
Que fait 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Entreprises avec année d'introduction en bourse similaire à 180 Life Sciences
- Acusensus Ltd a Année d'introduction en bourse de 2019
- Grayscale Ethereum Trust (ETH) a Année d'introduction en bourse de 2019
- Powerwrap Ltd a Année d'introduction en bourse de 2019
- Powerwrap a Année d'introduction en bourse de 2019
- National Rural Utilities Cooper a Année d'introduction en bourse de 2019
- Listed Funds Trust a Année d'introduction en bourse de 2019
- 180 Life Sciences a Année d'introduction en bourse de 2020
- Globally Local Technologies a Année d'introduction en bourse de 2021
- uniQure N.V a Année d'introduction en bourse de 2021
- Trustpilot plc a Année d'introduction en bourse de 2021
- IQVIA a Année d'introduction en bourse de 2021
- ACTIA S.A a Année d'introduction en bourse de 2021
- Remark a Année d'introduction en bourse de 2021